Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Glaukos Corporation (GKOS : NYSE)
 
 • Company Description   
Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company. Glaukos is focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. Glaukos developed Micro Invasive Glaucoma Surgery to serve as an alternative to the traditional glaucoma treatment and management paradigms. The company's iStent platform is the first MIGS device in the United States. Glaukos markets its products through direct sales force in the United States and other countries. It has distribution partners in Europe, the Asia Pacific, Latin America, and internationally.

Number of Employees: 995

 
 • Price / Volume Information   
Yesterday's Closing Price: $87.47 Daily Weekly Monthly
20 Day Moving Average: 636,786 shares
Shares Outstanding: 57.35 (millions)
Market Capitalization: $5,016.40 (millions)
Beta: 0.77
52 Week High: $163.71
52 Week Low: $77.10
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -3.96% -5.70%
12 Week -14.53% -22.40%
Year To Date -41.66% -47.91%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1 GLAUKOS WAY
-
ALISO VIEJO,CA 92656
USA
ph: 949-367-9600
fax: 949-367-9984
investors@glaukos.com http://www.glaukos.com
 
 • General Corporate Information   
Officers
Thomas W. Burns - Chief Executive Officer and Chairman
Alex R. Thurman - Senior Vice President & Chief Financial Officer
Mark J. Foley - Director
David F. Hoffmeister - Director
Marc A. Stapley - Director

Peer Information
Glaukos Corporation (ABMD)
Glaukos Corporation (DMDS)
Glaukos Corporation (CPWY.)
Glaukos Corporation (EQUR)
Glaukos Corporation (ECIA)
Glaukos Corporation (FMS)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED INSTRUMENTS
Sector: Medical
CUSIP: 377322102
SIC: 3841
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 06/01/25
Next Expected EPS Date: 11/03/25
Share - Related Items
Shares Outstanding: 57.35
Most Recent Split Date: (:1)
Beta: 0.77
Market Capitalization: $5,016.40 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.27 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.87 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 9.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 11/03/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 6.53
Price/Cash Flow: -
Price / Sales: 11.59
EPS Growth
vs. Year Ago Period: 53.85%
vs. Previous Quarter: -9.09%
Sales Growth
vs. Year Ago Period: 29.71%
vs. Previous Quarter: 16.37%
ROE
06/30/25 - -8.59
03/31/25 - -10.66
12/31/24 - -15.42
ROA
06/30/25 - -6.61
03/31/25 - -8.06
12/31/24 - -10.48
Current Ratio
06/30/25 - 5.51
03/31/25 - 6.49
12/31/24 - 5.99
Quick Ratio
06/30/25 - 4.69
03/31/25 - 5.62
12/31/24 - 5.22
Operating Margin
06/30/25 - -14.70
03/31/25 - -18.88
12/31/24 - -25.64
Net Margin
06/30/25 - -21.43
03/31/25 - -31.40
12/31/24 - -39.04
Pre-Tax Margin
06/30/25 - -21.28
03/31/25 - -30.40
12/31/24 - -37.97
Book Value
06/30/25 - 13.39
03/31/25 - 13.37
12/31/24 - 13.91
Inventory Turnover
06/30/25 - 1.70
03/31/25 - 1.68
12/31/24 - 1.68
Debt-to-Equity
06/30/25 - 0.09
03/31/25 - 0.09
12/31/24 - 0.09
Debt-to-Capital
06/30/25 - 8.25
03/31/25 - 8.30
12/31/24 - 8.31
 

Powered by Zacks Investment Research ©